Pharma-Bio Serv (PBSV) Common Equity (2016 - 2026)
Pharma-Bio Serv (PBSV) has disclosed Common Equity for 15 consecutive years, with $11.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Common Equity fell 13.13% year-over-year to $11.9 million, compared with a TTM value of $11.9 million through Oct 2025, down 13.13%, and an annual FY2025 reading of $11.9 million, down 13.13% over the prior year.
- Common Equity was $11.9 million for Q4 2025 at Pharma-Bio Serv, roughly flat from $11.9 million in the prior quarter.
- Across five years, Common Equity topped out at $23.8 million in Q3 2021 and bottomed at $11.9 million in Q4 2025.
- Average Common Equity over 5 years is $16.0 million, with a median of $16.0 million recorded in 2022.
- The sharpest move saw Common Equity increased 5.57% in 2021, then crashed 32.26% in 2022.
- Year by year, Common Equity stood at $18.9 million in 2021, then decreased by 12.46% to $16.6 million in 2022, then fell by 2.6% to $16.1 million in 2023, then fell by 14.95% to $13.7 million in 2024, then decreased by 13.13% to $11.9 million in 2025.
- Business Quant data shows Common Equity for PBSV at $11.9 million in Q4 2025, $11.9 million in Q3 2025, and $12.1 million in Q2 2025.